OmniAb, Inc.
OmniAb, Inc. (Nasdaq: OABI) licenses antibody-discovery technologies and research services to pharmaceutical and biotechnology companies and academic institutions developing therapeutics. Its platform uses genetically engineered animals, antigen-design methods, high-throughput single-cell screening and computational… From the company’s description.
Over the twelve months to Sep 30, 2026, OmniAb, Inc. reported revenue of $40.21M, up 90.6% from a year earlier, and a net loss of $43.47M. Its operating margin was −115.9%, and operations generated $2.67M in cash. In fiscal 2025, it reported revenue of $18.67M, down 29.3% from fiscal 2024, and a net loss of $64.78M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What OmniAb, Inc. does
In the company’s own words
OmniAb, Inc. (Nasdaq: OABI) licenses antibody-discovery technologies and research services to pharmaceutical and biotechnology companies and academic institutions developing therapeutics. Its platform uses genetically engineered animals, antigen-design methods, high-throughput single-cell screening and computational tools to identify human-sequence antibodies and other target-binding proteins. Offerings include discovery and screening systems, data analysis, optimization and ion-channel and transporter research, provided as integrated services or customizable technology access; agreements can generate access and service fees, milestones and royalties. The platform supports antibody formats and applications including bispecific and multispecific biologics, antibody-drug conjugates, CAR-T therapies, radiotherapeutics and peptides. Its technologies include OmniRat, OmniMouse, OmniChicken, OmniFlic, OmniClic, OmniTaur, OmnidAb, OmniUltra, xPloration and OmniDeep, alongside the OmniHub data portal. The company reports one business focused on its technology platform rather than multiple reportable segments. At December 31, 2025, it had 107 active partners and 407 active programs, including 27 antibodies in clinical development, two under regulatory review and three approved products developed by partners. Its website is https://www.omniab.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Professional Services
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1846253
- SIC
- 8731
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns OmniAb, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · OmniAb, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do OmniAb, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of OmniAb, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in OmniAb, Inc.'s last four quarterly filings that the numbers alone won't show?”